The carrying amount of goodwill at March 31, 2020 and 2019 was $32.0 million and $32.6 million, respectively, and has been recorded in connection with the Company’s acquisitions of Impella Cardiosystems AG, in May 2005 and ECP and AIS in July 2014. The goodwill activity is as follows:

	(in $000's)
Balance at March 31, 2018	$	35,808
Foreign currency translation impact		(3,207	)
Balance at March 31, 2019	$	32,601
Foreign currency translation impact		(632	)
Balance at March 31, 2020	$	31,969

The carrying amount of In-Process Research and Development (“IPR&D”) assets at March 31, 2020 and 2019 was $14.9 million and $15.2 million, respectively, and was recorded in conjunction with the Company’s acquisition of ECP and AIS, in July 2014. The estimated fair value of IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows for the future Impella ECP™ expandable catheter pump technology were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development.

The carrying value of the Company’s IPR&D assets and the change in the balance for the fiscal years ended March 31, 2020 and 2019 are as follows:

	(in $000's)
Balance at March 31, 2018	$	16,705
Foreign currency translation impact		(1,497	)
Balance at March 31, 2019	$	15,208
Foreign currency translation impact		(295	)
Balance at March 31, 2020	$	14,913

	Fiscal Years Ended March 31,
	2020		2019
	(in $000's)
Investment in Shockwave Medical	$	55,704	$	56,195
Other investments		38,741		24,584
Operating lease right-of-use assets (Note 9)		11,760		—
Cross-currency swap (Note 4)		3,786		—
Other intangible assets and other assets		7,664		4,336
Total other assets	$	117,655	$	85,115

In fiscal 2019, the Company invested $25.0 million in medical device company Shockwave Medical, which is publicly-traded and carried at fair value with changes in fair value recorded in other (expense) income. The fair value of this investment as of March 31, 2020 and 2019 was $55.7 million and $56.2 million. Amounts recorded in other income (expense) were $0.5 million and $31.2 for the years ended March 31, 2020 and 2019, respectively.

The carrying value of the Company’s portfolio of other investments and the change in the balance for fiscal years ended March 31, 2020, 2019 and 2017 were as follows:

	Fiscal Years Ended March 31,
		2020			2019			2018
	(in $000's)
Beginning balance	$	24,584		$	12,649		$	7,249
Additions		19,599			14,935			6,400
Disposals		(750	)		(1,966	)		—
Change in fair value, net		(4,692	)		(1,034	)		(1,000	)
Ending balance	$	38,741		$	24,584		$	12,649

Included in other (expense) income is impairment losses of $4.7 million relating to certain of the Company’s investment in other private medical device companies.

As of March 31, 2020, the Company’s other intangible assets and other assets is comprised primarily of license manufacturing rights to certain technology from third parties and other long-term assets such as prepaid expenses. During fiscal 2020, the Company made payments totaling $4.1 million to license manufacturing rights to certain technology from third parties. These intangible assets are classified with other assets in the Company’s consolidated balance sheet and are amortized over their useful life of 15 years.

Amortization expense related to intangibles assets was $0.2 million for each of the fiscal years ended March 31, 2020 and 2019. There was no amortization expense for the years ended March 31, 2018.